SALT LAKE CITY, June 30, 2011 /PRNewswire/ -- LifeVantage Corporation (OTCBB: LFVN), the maker of science-based solutions for the reduction of oxidative stress by the synergistic activation of Nrf2, announced today that renowned scientist, co-discoverer of superoxide dismutase and a pioneer in the area of Free Radical Biology, Dr.

FREMONT, Calif., May 17, 2011 /PRNewswire/ -- WaferGen Biosystems, Inc.

CAMBRIDGE, England, April 21, 2011 /PRNewswire/ -- - First-time-in-man Study Initiated Ahead of Schedule Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines, today announced that the first-time-in-man Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated and dosing has begun. The trial is a randomised, placebo controlled Phase I study to investigate the pharmacokinetics, safety and tolerability of single ascending orally administered doses of CNV2197944.

SAN DIEGO, March 1, 2011 /PRNewswire/ -- aTyr Pharma, the Physiocrine therapeutics company, today announced the formation of a therapeutic advisory board. The members are Drs. Thomas O. Daniel, L.

- Dr. Mark Reisman named chief scientific officer and head of research SEATTLE, Sept. 8 /PRNewswire-USNewswire/ -- Today, Swedish announced it is expanding its research program to benefit more patients in the Pacific Northwest region.